401 related articles for article (PubMed ID: 18541230)
1. Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
Yamashita J; Nakajima K; Ohno Y; Kaneshiro Y; Matsuo T; Tanaka H; Kaneko K
Eur J Pharmacol; 2008 Jul; 589(1-3):239-44. PubMed ID: 18541230
[TBL] [Abstract][Full Text] [Related]
2. Effects of aminonucleoside, daunomycin, and adriamycin on carbon oxidation by glomeruli.
Kaplan BS; Renaud L; Drummond KN
Lab Invest; 1976 Feb; 34(2):174-8. PubMed ID: 1249918
[TBL] [Abstract][Full Text] [Related]
3. Unilateral renal disease in the rat. I. Clinical, morphologic, and glomerular mesangial functional features of the experimental model produced by renal perfusion with aminonucleoside.
Hoyer JR; Mauer SM; Michael AF
J Lab Clin Med; 1975 May; 85(5):756-68. PubMed ID: 1091713
[TBL] [Abstract][Full Text] [Related]
4. Melatonin decreases apoptosis and expression of apoptosis-associated proteins in acute puromycin aminonucleoside nephrosis.
Pedreañez A; Rincón J; Romero M; Viera N; Mosquera J
Nephrol Dial Transplant; 2004 May; 19(5):1098-105. PubMed ID: 14993511
[TBL] [Abstract][Full Text] [Related]
5. Blunted renal dopaminergic system activity in puromycin aminonucleoside-induced nephrotic syndrome.
Sampaio-Maia B; Moreira-Rodrigues M; Serrão P; Pestana M
Nephrol Dial Transplant; 2006 Feb; 21(2):314-23. PubMed ID: 16204272
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia, and renin-angiotensin-aldosterone system on sodium retention.
Pedraza-Chaverrí J; Cruz C; Ibarra-Rubio ME; Chávez MT; Calleja C; Tapia E; del Carmen Uribe M; Romero L; Peña JC
Rev Invest Clin; 1990; 42(1):29-38. PubMed ID: 2236972
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of aminonucleoside nephrosis in rats. IV. Prevention by N6-methyladenosine.
Derr RF; Loechler DK; Alexander CS; Nagasawa HT
J Lab Clin Med; 1968 Sep; 72(3):363-9. PubMed ID: 5674067
[No Abstract] [Full Text] [Related]
8. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression.
Eto N; Wada T; Inagi R; Takano H; Shimizu A; Kato H; Kurihara H; Kawachi H; Shankland SJ; Fujita T; Nangaku M
Kidney Int; 2007 Aug; 72(4):455-63. PubMed ID: 17457371
[TBL] [Abstract][Full Text] [Related]
9. Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol.
Ricardo SD; Bertram JF; Ryan GB
Exp Nephrol; 1995; 3(5):270-9. PubMed ID: 7583048
[TBL] [Abstract][Full Text] [Related]
10. Time course of lipid peroxidation in puromycin aminonucleoside-induced nephropathy.
Fawcett JP; Jiang R; Walker RJ
Res Commun Mol Pathol Pharmacol; 1994 Nov; 86(2):227-34. PubMed ID: 7881871
[TBL] [Abstract][Full Text] [Related]
11. The renal clearance of dextran sulfate decreases in puromycin aminonucleoside-induced glomerulosclerosis: a puzzle observation.
Santos AM; Pomin VH; Stelling MP; Guimarães MA; Cardoso LR; Mourão PA
Clin Chim Acta; 2007 Aug; 383(1-2):116-25. PubMed ID: 17599817
[TBL] [Abstract][Full Text] [Related]
12. Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats.
Yatsu T; Aoki M; Tanaka A
Eur J Pharmacol; 2005 Mar; 510(1-2):121-6. PubMed ID: 15740732
[TBL] [Abstract][Full Text] [Related]
13. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome.
Aizawa K; Takeda S; Tashiro Y; Yorozu K; Hirata M; Kanada H; Moriguchi Y; Endo K
Am J Nephrol; 2012; 36(5):419-26. PubMed ID: 23128049
[TBL] [Abstract][Full Text] [Related]
14. Studies on the effectiveness of sairei-to on puromycin aminonucleoside nephrosis in rats.
Joarder ZH; Ogawa T; Yorioka N; Yamakido M
Hiroshima J Med Sci; 1991 Dec; 40(4):127-35. PubMed ID: 1797743
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship for two lipoxygenase inhibitors and their potential for inducing nephrotic syndrome.
Morley TJ; Evans GO; Goodwin DA; Read NG; Hodgson ST; Hawksworth GM
Toxicol Appl Pharmacol; 1997 Oct; 146(2):299-308. PubMed ID: 9344898
[TBL] [Abstract][Full Text] [Related]
16. Effect of dietary antioxidants on puromycin aminonucleoside nephrotic syndrome.
Pedraza-Chaverri J; Arévalo AE; Hernández-Pando R; Larriva-Sahd J
Int J Biochem Cell Biol; 1995 Jul; 27(7):683-91. PubMed ID: 7648424
[TBL] [Abstract][Full Text] [Related]
17. [Cytophotometric studies of the kidneys in aminonucleoside nephrosis in rats after administration of nitrogranulogen].
Fydryk J; Stachów J; Chlebcewicz-Szuba W; Krygier-Stojałowska A
Patol Pol; 1988; 39(1):13-25. PubMed ID: 3412819
[No Abstract] [Full Text] [Related]
18. DMSO potentiates aminonucleoside of puromycin nephrosis in rats.
Spear GS; Nguyen D; Conklin S; Wikle JS; Fan J; Lan YH; Allen J; Reineck S
J Pathol; 1987 Oct; 153(2):183-7. PubMed ID: 3694323
[TBL] [Abstract][Full Text] [Related]
19. Plantago asiatica L. Ameliorates Puromycin Aminonucleoside-Induced Nephrotic Syndrome by Suppressing Inflammation and Apoptosis.
Kho MC; Park JH; Han BH; Tan R; Yoon JJ; Kim HY; Ahn YM; Lee YJ; Kang DG; Lee HS
Nutrients; 2017 Apr; 9(4):. PubMed ID: 28420111
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of 35sulfate into the glomerular basement membrane in puromycin aminonucleoside nephrosis.
Garin EH; Boggs KP; Burke FC
Int J Pediatr Nephrol; 1985; 6(2):117-20. PubMed ID: 4030221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
